Lucienne Chatenoud - Concepedia

Author

Lucienne Chatenoud

Also Known As

Chatenoud, L., Chatenoud, Lucienne, L CHATENOUD, L Chatenoud, L M Chatenoud, L. CHATENOUD, L. Chatenoud, L. chatenoud, LUCIENNE CHATENOUD, Lucienne Chatenoud

418

Publications

18.5K

Citations

H-Index

182

Concepts

All Affiliations

Inserm Hôpital Necker-Enfants Malades Université Paris Cité Centre National de la Recherche Scientifique Délégation Paris 5

About

Lucienne Chatenoud is an author at Inserm specializing in medicine, immunology, and autoimmunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	49	104	9.3K
2	Allergy	25	35	3.3K
3	Health Sciences	8	8	1.9K
4	Language Studies	2	2	30
5	Public Health	1	1	46

Lucienne Chatenoud

168

Publications

15.2K

Citations

H-Index

Page 1

	Year	Citations
Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes Bart Keymeulen, Evy Vandemeulebroucke, Anette G. Ziegler, New England Journal of Medicine	2005	1.1K
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition) Andrea Cossarizza, Hyun‐Dong Chang, Andreas Radbruch, European Journal of Immunology Laboratory ImmunologyImmunologyPathologyImmunophenotypingImmune System	2019	965
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Lucienne Chatenoud, Éric Thervet, J Primo, Proceedings of the National Academy of Sciences ImmunologyPathologyImmunotherapyNonobese Diabetic MiceImmune Dysregulation	1994	646
TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes Mériam Belghith, Jeffrey A. Bluestone, Samia Barriot, Nature Medicine Overt Autoimmune DiabetesAutoimmune DiseaseAutoantibody ProductionDiabetesImmunology	2003	581
IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells Yenkel Grinberg‐Bleyer, Audrey Baeyens, Sylvaine You, The Journal of Experimental Medicine	2010	415
CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice Lucienne Chatenoud, J Primo, J F Bach The Journal of Immunology	1997	414
IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION Lucienne Chatenoud, Christiane Ferran, Christophe Legendre, Transplantation ImmunologyImmune RegulationCell DeathPathologyRenal Inflammation	1990	319
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass Bart Keymeulen, Melanie Walter, Chantal Mathieu, Diabetologia ObesityMetabolic SyndromeDiabetes ManagementBody CompositionAutoimmune Disease	2010	310
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19 Thomas Hueso, Cécile Pouderoux, Hélène Péré, Blood	2020	297
Cytokine‐related syndrome following injection of anti‐CD3 monoclonal antibody: Further evidence for transient <i>in vivo</i> T cell activation Christiane Ferran, Kathleen C. F. Sheehan, Michel Dy, European Journal of Immunology Laboratory ImmunologyCellular ImmunologyImmunologyImmune RegulationPathology	1990	263

Page 1